COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Regeneron (RCT)38%0.62 [0.18-2.09]recov. time9291Improvement, RR [CI]TreatmentControlRegeneron (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Weinreich (RCT)67%0.33 [0.03-3.17]death1/1,3553/1,341Webb98%0.02 [0.00-0.27]death0/11557/5,536Tau​2 = 0.39; I​2 = 45.7%Early treatment72%0.28 [0.11-0.71]19/2,917122/8,30972% improvementHorby (RCT)6%0.94 [0.86-1.03]death944/4,8391,026/4,946Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.86-1.03]944/4,8391,026/4,9466% improvementRegeneron (RCT)94%0.06 [0.00-1.10]symp. case0/1868/223Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP94%0.06 [0.00-1.10]0/1868/22394% improvementRegeneron (DB RCT)89%0.11 [0.01-2.06]hosp./ER0/7534/752Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP89%0.11 [0.01-2.06]0/7534/75289% improvementAll studies69%0.31 [0.13-0.76]963/8,6951,160/14,23069% improvement7 casirivimab/imdevimab COVID-19 studiesc19regn.com 7/26/21Tau​2 = 0.75; I​2 = 82.3%; Z = 2.58 (p = 0.005)Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Weinreich (RCT)67%0.33 [0.03-3.17]1/1,3553/1,341Improvement, RR [CI]TreatmentControlWebb98%0.02 [0.00-0.27]0/11557/5,536Tau​2 = 2.75; I​2 = 62.2%Early treatment92%0.08 [0.00-1.53]1/1,47060/6,87792% improvementHorby (RCT)6%0.94 [0.86-1.03]944/4,8391,026/4,946Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.86-1.03]944/4,8391,026/4,9466% improvementAll studies76%0.24 [0.03-2.14]945/6,3091,086/11,82376% improvement3 casirivimab/imdevimab COVID-19 mortality resultsc19regn.com 7/26/21Tau​2 = 2.75; I​2 = 77.4%; Z = 1.27 (p = 0.1)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Webb91%0.09 [0.01-0.63]hosp.1/115538/5,536Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment91%0.09 [0.01-0.63]1/115538/5,53691% improvementAll studies91%0.09 [0.01-0.63]1/115538/5,53691% improvement1 casirivimab/imdevimab COVID-19 hospitalization resultc19regn.com 7/26/21Tau​2 = 0.00; I​2 = 0.0%; Z = 2.42 (p = 0.0077)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Regeneron (RCT)48%0.52 [0.25-1.07]10/18623/223Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP48%0.52 [0.25-1.07]10/18623/22348% improvementAll studies48%0.52 [0.25-1.07]10/18623/22348% improvement1 casirivimab/imdevimab COVID-19 case resultc19regn.com 7/26/21Tau​2 = 0.00; I​2 = 0.0%; Z = 1.78 (p = 0.037)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Regeneron (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Improvement, RR [CI]TreatmentControlWeinreich (RCT)67%0.33 [0.03-3.17]death1/1,3553/1,341Webb98%0.02 [0.00-0.27]death0/11557/5,536Tau​2 = 0.81; I​2 = 48.7%Early treatment82%0.18 [0.04-0.72]19/2,825122/8,21882% improvementHorby (RCT)6%0.94 [0.86-1.03]death944/4,8391,026/4,946Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.86-1.03]944/4,8391,026/4,9466% improvementRegeneron (DB RCT)89%0.11 [0.01-2.06]hosp./ER0/7534/752Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP89%0.11 [0.01-2.06]0/7534/75289% improvementAll studies70%0.30 [0.10-0.87]963/8,4171,152/13,91670% improvement5 casirivimab/imdevimab COVID-19 serious outcomesc19regn.com 7/26/21Tau​2 = 0.84; I​2 = 86.8%; Z = 2.22 (p = 0.013)Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Regeneron (RCT)38%0.62 [0.18-2.09]recov. time9291Improvement, RR [CI]TreatmentControlRegeneron (RCT)54%0.46 [0.15-1.43]recov. time9291Regeneron (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Regeneron (RCT)70%0.30 [0.13-0.68]hosp./death7/73624/748Regeneron (RCT)29%0.71 [0.60-0.85]recov. time1,3551,341Regeneron (RCT)29%0.71 [0.60-0.85]recov. time736748Weinreich (RCT)67%0.33 [0.03-3.17]death1/1,3553/1,341Weinreich (RCT)39%0.61 [0.06-5.83]death1/7363/1,341Weinreich (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Weinreich (RCT)70%0.30 [0.13-0.68]hosp./death7/73624/748Weinreich (RCT)29%0.71 [0.60-0.85]recov. time1,3551,341Weinreich (RCT)29%0.71 [0.60-0.85]recov. time736748Webb98%0.02 [0.00-0.27]death0/11557/5,536Webb91%0.09 [0.01-0.63]hosp.1/115538/5,536Horby (RCT)6%0.94 [0.86-1.03]death944/4,8391,026/4,946Horby (RCT)0%1.00 [0.89-1.13]ventilation479/4,556487/4,642Horby (RCT)20%0.80 [0.70-0.91]death396/1,633451/1,520Horby (RCT)12%0.88 [0.73-1.06]ventilation189/1,599200/1,484Regeneron (RCT)94%0.06 [0.00-1.10]symp. case0/1868/223Regeneron (RCT)48%0.52 [0.25-1.07]cases10/18623/223Regeneron (DB RCT)89%0.11 [0.01-2.06]hosp./ER0/7534/752Regeneron (DB RCT)81%0.19 [0.10-0.35]symp. case11/75359/752Regeneron (DB RCT)62%0.38 [0.22-0.63]recov. time753752Regeneron (DB RCT)69%0.31 [0.17-0.57]viral time753752casirivimab/imdevimab COVID-19 outcomesc19regn.com 7/26/21Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit